BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

723 related articles for article (PubMed ID: 15344963)

  • 1. Long-term follow-up of pediatric transplant recipients: mycophenolic acid trough levels are not a good indicator for long-term graft function.
    Pape L; Ehrich JH; Offner G
    Clin Transplant; 2004 Oct; 18(5):576-9. PubMed ID: 15344963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
    Cortinovis M; Gotti E; Pradini S; Gaspari F; Perico N
    Transplantation; 2011 Sep; 92(5):550-6. PubMed ID: 21709602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is the intrapatient variability of mycophenolic acid trough levels?
    Todorova EK; Huang SH; Kobrzynski MC; Filler G
    Pediatr Transplant; 2015 Nov; 19(7):669-74. PubMed ID: 26201386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients.
    Barau C; Barrail-Tran A; Hemerziu B; Habes D; Taburet AM; Debray D; Furlan V
    Liver Transpl; 2011 Oct; 17(10):1152-8. PubMed ID: 21695772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001 Jan; 47(1):88-94. PubMed ID: 11148182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients.
    Aw MM; Brown NW; Itsuka T; Gonde CE; Adams JE; Heaton ND; Tredger JM; Mieli-Vergani G; Dhawan A
    Liver Transpl; 2003 Apr; 9(4):383-8. PubMed ID: 12682891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity.
    Filler G; Gellermann J; Zimmering M; Mai I
    Transpl Int; 2000; 13(3):201-6. PubMed ID: 10935703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil.
    Dipchand AI; Pietra B; McCrindle BW; Rosebrook-Bicknell HL; Boucek MM
    J Heart Lung Transplant; 2001 Oct; 20(10):1035-43. PubMed ID: 11595558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine.
    Capone D; Tarantino G; Kadilli I; Polichetti G; Basile V; Federico S; Sabbatini M
    Nephrol Dial Transplant; 2011 Sep; 26(9):3019-25. PubMed ID: 21317409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term changes in mycophenolic acid exposure in combination with tacrolimus and corticosteroids are dose dependent and not reflected by trough plasma concentration: a prospective study in 100 de novo renal allograft recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    J Clin Pharmacol; 2003 Aug; 43(8):866-80. PubMed ID: 12953344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis.
    Benz K; Plank C; Griebel M; Montoya C; Dötsch J; Klare B
    Pediatr Transplant; 2006 May; 10(3):331-6. PubMed ID: 16677357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.
    Weber LT; Shipkova M; Lamersdorf T; Niedmann PD; Wiesel M; Mandelbaum A; Zimmerhackl LB; Schütz E; Mehls O; Oellerich M; Armstrong VW; Tönshoff B
    J Am Soc Nephrol; 1998 Aug; 9(8):1511-20. PubMed ID: 9697675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental changes of MPA exposure in children.
    Yoo EC; Alvarez-Elías AC; Todorova EK; Filler G
    Pediatr Nephrol; 2016 Jun; 31(6):975-82. PubMed ID: 26743220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients.
    Ghio L; Ferraresso M; Viganò SM; Ginevri F; Perfumo F; Gianoglio B; Murer L; Zacchello G; Dello Strologo L; Cardillo M; Tirelli S; Valente U; Edefonti A
    Transplant Proc; 2005 Mar; 37(2):856-8. PubMed ID: 15848555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.
    Merkel U; Lindner S; Vollandt R; Sperschneider H; Balogh A
    Int J Clin Pharmacol Ther; 2005 Aug; 43(8):379-88. PubMed ID: 16119513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.